JP2019527729A5 - - Google Patents

Download PDF

Info

Publication number
JP2019527729A5
JP2019527729A5 JP2019522614A JP2019522614A JP2019527729A5 JP 2019527729 A5 JP2019527729 A5 JP 2019527729A5 JP 2019522614 A JP2019522614 A JP 2019522614A JP 2019522614 A JP2019522614 A JP 2019522614A JP 2019527729 A5 JP2019527729 A5 JP 2019527729A5
Authority
JP
Japan
Prior art keywords
formulation
polypropylene glycol
therapeutic
ppm
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/041691 external-priority patent/WO2018013673A1/en
Publication of JP2019527729A publication Critical patent/JP2019527729A/ja
Publication of JP2019527729A5 publication Critical patent/JP2019527729A5/ja
Pending legal-status Critical Current

Links

JP2019522614A 2016-07-13 2017-07-12 治療用タンパク質製剤のための安定化賦形剤 Pending JP2019527729A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662361793P 2016-07-13 2016-07-13
US62/361,793 2016-07-13
PCT/US2017/041691 WO2018013673A1 (en) 2016-07-13 2017-07-12 Stabilizing excipients for therapeutic protein formulations

Publications (2)

Publication Number Publication Date
JP2019527729A JP2019527729A (ja) 2019-10-03
JP2019527729A5 true JP2019527729A5 (https=) 2020-08-06

Family

ID=60941865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522614A Pending JP2019527729A (ja) 2016-07-13 2017-07-12 治療用タンパク質製剤のための安定化賦形剤

Country Status (6)

Country Link
US (4) US10279048B2 (https=)
EP (1) EP3484520A4 (https=)
JP (1) JP2019527729A (https=)
KR (1) KR20190027878A (https=)
CA (1) CA3030422C (https=)
WO (1) WO2018013673A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2019036619A1 (en) * 2017-08-18 2019-02-21 Reform Biologics, Llc STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN
EP3761962A4 (en) * 2018-03-07 2021-12-15 ReForm Biologics, Inc. EXCIPIENT COMPOUNDS FOR PROTEIN-BASED FORMULATIONS
WO2019180561A1 (en) 2018-03-20 2019-09-26 Mankind Pharma Ltd. Stable pharmaceutical composition of vasopressin
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
EP3852724A4 (en) 2018-09-20 2022-07-06 Levo Therapeutics, Inc. CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
TW202031283A (zh) 2018-09-20 2020-09-01 馬克 Ｃ 曼寧 穩定卡貝縮宮素鼻內製劑
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
CN113710794B (zh) 2019-04-19 2024-08-09 富士胶片株式会社 细胞外囊泡的保存稳定化剂及保存稳定化方法
CN116133689A (zh) * 2020-07-07 2023-05-16 豪夫迈·罗氏有限公司 作为治疗性蛋白质制剂的稳定剂的替代表面活性剂
US20250275967A1 (en) * 2022-04-22 2025-09-04 Janssen Sciences Ireland Unlimited Company Freeze dried compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2510633C3 (de) * 1975-03-12 1978-07-13 Boehringer Mannheim Gmbh, 6800 Mannheim Diagnostisches Mittel zum Nachweis von Eiweiß in Körperflüssigkeiten und dafür geeignete Indikatorfarbstoffe
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US6039977A (en) 1997-12-09 2000-03-21 Alza Corporation Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods
EP1372611B1 (en) * 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
US7041088B2 (en) 2002-10-11 2006-05-09 Ethicon, Inc. Medical devices having durable and lubricious polymeric coating
DE10325198B4 (de) 2003-06-04 2007-10-25 Clariant Produkte (Deutschland) Gmbh Verwendung von alkoxylierten vernetzten Polyglycerinen als biologisch abbaubare Emulsionsspalter
US8025915B2 (en) 2006-01-11 2011-09-27 Schott Ag Method of preparing a macromolecule deterrent surface on a pharmaceutical package
CN101889209A (zh) 2007-10-22 2010-11-17 贝克顿·迪金森公司 评价在含有机基聚硅氧烷的悬浮液中蛋白质聚集的方法和用含蛋白质溶液的有机基聚硅氧烷涂布的医疗制品
WO2009065126A2 (en) 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
AU2010277559B2 (en) * 2009-07-31 2016-08-11 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
BR112012027361A2 (pt) * 2010-04-27 2021-04-27 Scil Technology Gmbh formulação mia/cd-rap estável.
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
WO2012135035A1 (en) * 2011-03-25 2012-10-04 Amgen Inc. Anti - sclerostin antibody crystals and formulations thereof
SG10201606990TA (en) 2012-05-31 2016-10-28 Agency Science Tech & Res Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
US9119858B2 (en) * 2012-08-21 2015-09-01 Genesys Research Institute, Inc. Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6026002B2 (ja) 2012-11-27 2016-11-16 アルテオジェン インコーポレイテッド タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物
US20140342006A1 (en) 2013-03-15 2014-11-20 Ansun Biopharma, Inc. Methods for Preparing Injectable Protein Microparticle Suspensions
US20160068609A1 (en) * 2013-04-22 2016-03-10 Glycotope Gmbh Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
WO2015196091A1 (en) * 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations

Similar Documents

Publication Publication Date Title
JP2019527729A5 (https=)
EP2525787B1 (en) Liquid formulations for long-acting g-csf conjugate
Rajoria et al. In-situ gelling system: a novel approach for ocular drug delivery
US9682149B2 (en) Stabilizer for hyaluronidase and liquid formulation comprising hyaluronidase
JP2016530321A5 (ja) イオン性液体を含有する注射用液状タンパク質製剤およびその使用
KR20140091707A (ko) 크실리톨로 안정화된 에타너셉트 제형
JP7223712B2 (ja) 安定なペプチド組成物
KR20190027878A (ko) 치료 단백질 제제용 안정화 부형제
CN104159614A (zh) TNF-α抗体的药物制剂
US20160120946A1 (en) Compositions comprising gc-macrophage activating factor and uses thereof
JP2019532949A (ja) 耐熱保護剤、室温で保存可能な豚コレラ生ワクチンの製造方法及びその使用
MX2015005230A (es) Composicion farmaceutica estable de peginterferon alfa-2b.
CN112656939B (zh) 一种针对血管内皮生长因子的人源化抗体的药物组合物
EP4003290B1 (en) Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
JPWO2000000221A1 (ja) 水溶性乾燥組成物
CN105412942A (zh) 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
CN115518151A (zh) 一种人类免疫缺陷病毒中和抗体制剂及其用途
US11229702B1 (en) High concentration formulations of adalimumab
CN101376022A (zh) 含聚乙二醇降纤酶的药物组合物
WO1999045953A1 (fr) Compositions contenant un cofacteur ii de l'heparine et techniques de stabilisation
Deane The role of mast cell proteases in respiratory disease
CN110799188A (zh) 基于托品酰胺的眼用制剂
HK1175721A (en) Liquid formulations for long-acting g-csf conjugate